Third COVID-19 Booster For Thais Will Come From Locally-Produced Vaccines

Next year, Thais are expected to receive locally developed Covid-19 vaccines as a third booster vaccine.
The three Thai-made vaccines have not yet been subjected to clinical trials. Therefore, they cannot be used to combat the current wave of Covid-19 outbreak or to ease the vaccine shortage crisis.
Even so, researchers behind the domestic vaccine effort say they can still make a significant contribution to long-term efforts to stop Covid-19 and improve the country’s ability to fight such diseases in the future.
One of these efforts is Baiya Phytopharm’s development of plant-based subunit vaccines.
A vaccine of this type is produced by shaping plant proteins from the leaves of tobacco trees to resemble the shape of the Covid-19 virus. When the vaccine is injected into the body, our immune system will react to the modified protein and build immunity against the Covid-19 virus, which has a similar structure.
The vaccine has already been shown to prevent Covid-19 infections in animals.
Phytopharm’s vaccine still needs to be tested on humans before it can be registered and approved for public use.
The human trials will begin in August with 100 volunteers, and the vaccines are expected to be available by next year, a Baiya Phytopharm spokesperson said.
“In the meantime, Baiya Phytopharm is developing a second-generation vaccine to deal with new strains of the virus.”
Chula-Cov 19 developed by Chulalongkorn University’s Centre of Excellence in Vaccine Research and Development, and NDV-HXP-S, developed by the Government Pharmaceutical Organization (GPO), are available.
According to Assistant Professor Suthira Taychakhoonavudh, the researcher at Chulalongkorn University’s Faculty of Pharmaceutical Science and CEO of Baiya Phytopharm, Thais will have more vaccine options from next year once Thai vaccines enter the market.
When the vaccines are expected to be approved in 2022, many people will have already received their first dose of the Covid-19 vaccine, and they will need another shot to maintain their immunity.
Our research and development work focuses on the long-term sustainability of Thailand’s public health, as our technology can be applied to produce vaccines against other contagious diseases, according to Baiya Phytopharm.
According to Professor Kiat Ruxrungtham, head of Chulalongkorn University’s vaccine research center, the public health sector needs vaccine production technology that includes local bases. “It may be too late to solve our immediate problems, but it is important for the country’s future and health security to be able to produce vaccines ourselves,” he said.
“In the event of another pandemic, we will have the capability to promptly prepare our own vaccines, so we will not have to rely on imported vaccines.”
Thailand could become Asia’s vaccine hub. Thailand could become a major supplier of mRNA vaccines in the region by creating the Chula-Cov 19 vaccine, the first mRNA vaccine developed and produced in Southeast Asia.
According to him, the Chula-Cov 19 vaccine will be available by the first quarter of 2022, or by the third quarter at the latest. Human trials and the Thailand Food and Drug Administration’s vaccine approval process are required.
Chula-Cov 19 is an mRNA vaccine, similar to Pfizer and Moderna vaccines, which teach our cells how to make proteins that trigger an immune response against the Covid-19 virus inside our bodies.
The vaccine research center of Chulalongkorn University has partnered with BioNet-Asia Co Ltd to oversee the production of the vaccines. It will be deployed in the first phase of human trials, beginning this month, after 10,000 doses of the drug have been manufactured.
According to tests on monkeys and mice, the vaccine is 100% effective after two doses. In addition, they are developing a second-generation to cover new strains of Covid-19.
According to GPO managing director Withoon Danwiboon, the NDV-HXP-S vaccine is now in the second phase of human trials. The vaccine could be available early next year. An NDV-HXP-S vaccine is made from the genetically modified Newcastle disease virus, which focuses on a stabilized spike protein on the surface of the coronavirus.
Dr. Withoon said GPO’s vaccine factory already produces influenza vaccines. The GPO’s industrial-scale plant can produce 25-30 million doses per year, so mass production of the Covid-19 vaccine can begin immediately.

Tags: , , , ,


%d bloggers like this: